Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer

Next Previous
Trial Profile

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Capecitabine; Carboplatin; Cyclophosphamide; Eribulin; Gemcitabine; Interferon; Retifanlimab; Taxanes; Vinorelbine
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASTRO-VAC CNS; BRIA-ABC
  • Sponsors BriaCell Therapeutics Corp

Most Recent Events

  • 06 Jan 2026 Planned End Date changed from 1 Jun 2026 to 1 Jun 2028.
  • 06 Jan 2026 Planned primary completion date changed from 1 Jan 2026 to 1 Dec 2027.
  • 18 Dec 2025 According to BriaCell Therapeutics media release, clinical trial independently featured in the Nature Medicine Year In Review's publication, "Eleven clinical trials that will shape medicine in 2026". BriaCell anticipates reporting top line data as early as H1-2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top